• Product name
    Anti-DR4 antibody [DR-4-02] (FITC)
    See all DR4 primary antibodies
  • Description
    Mouse monoclonal [DR-4-02] to DR4 (FITC)
  • Host species
  • Conjugation
    FITC. Ex: 493nm, Em: 528nm
  • Specificity
    The antibody recognizes TRAIL R1 (DR4), a human death receptor 4 (468 amino acids) expressed in most human tissues (spleen, peripheral blood leucocytes, thymus) and in a variety of tumour derived cell lines.
  • Tested applications
    Suitable for: IP, Functional Studies, Flow Cytmore details
  • Species reactivity
    Reacts with: Human
  • Immunogen

    Fusion protein (Human) containing the extracellular part of DR4 and the constant part of the heavy chain of human IgG1.

  • General notes
    Do not use after expiration date stamped on vial label. Short term exposure to room temperature should not affect the quality of the reagent. However, if reagent is stored under any conditions other than those specified, the conditions must be verified by the user.

    Soluble antibody blocks DR4 receptor against TRAIL induced apoptosis. Plastic immobilized antibody induces apoptosis in sensitive cells.

    The purified antibody is conjugated with Fluorescein isothiocyanate (FITC) under optimum conditions. The reagent is free of unconjugated FITC and adjusted for direct use. No reconstitution is necessary.


  • Form
  • Storage instructions
    Shipped at 4°C. Store at +4°C.
  • Storage buffer
    Preservative: 0.097% Sodium azide
    Constituent: 0.2% BSA

    0.2% high grade protease free BSA
  • Concentration information loading...
  • Purity
    Size exclusion
  • Purification notes
    The antibody was >95% pure prior to conjugation as determined from SDS-PAGE (by protein A affinity chromatography).
  • Primary antibody notes
    Soluble antibody blocks DR4 receptor against TRAIL induced apoptosis. Plastic immobilized antibody induces apoptosis in sensitive cells.
  • Clonality
  • Clone number
  • Isotype
  • Research areas


Our Abpromise guarantee covers the use of ab59047 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
IP Use at an assay dependent concentration.
Functional Studies Use a concentration of 2 - 3 µg/ml. in cultivation medium. Final concentration of TRAIL: 20-200 ng/ml. Note: It is recommended that the antibody is added 15 min before the addition of TRAIL.
Flow Cyt Use a concentration of 5 µg/ml.

ab91356 - Mouse monoclonal IgG1, is suitable for use as an isotype control with this antibody.



  • Function
    Receptor for the cytotoxic ligand TNFSF10/TRAIL. The adapter molecule FADD recruits caspase-8 to the activated receptor. The resulting death-inducing signaling complex (DISC) performs caspase-8 proteolytic activation which initiates the subsequent cascade of caspases (aspartate-specific cysteine proteases) mediating apoptosis. Promotes the activation of NF-kappa-B.
  • Tissue specificity
    Widely expressed. High levels are found in spleen, peripheral blood leukocytes, small intestine and thymus, but also in K562 erythroleukemia cells, MCF7 breast carcinoma cells and activated T-cells.
  • Sequence similarities
    Contains 1 death domain.
    Contains 3 TNFR-Cys repeats.
  • Cellular localization
  • Information by UniProt
  • Database links
  • Alternative names
    • Apo2 antibody
    • CD261 antibody
    • Cytotoxic TRAIL receptor antibody
    • Death receptor 4 antibody
    • DR4 antibody
    • NF related apoptosis-inducing ligand receptor 1 antibody
    • TNF receptor superfamily member 10a antibody
    • TNF-related apoptosis-inducing ligand receptor 1 antibody
    • TNFRSF10A antibody
    • TR10A_HUMAN antibody
    • TRAIL receptor 1 antibody
    • TRAIL-R1 antibody
    • TRAILR 1 antibody
    • TRAILR1 antibody
    • Tumor necrosis factor receptor superfamily member 10A antibody
    • Tumor necrosis factor receptor superfamily member 10a variant 2 antibody
    • Tumor necrosis factor receptor superfamily, member 10a antibody
    see all


This product has been referenced in:
  • Strekalova E  et al. Preclinical Breast Cancer Models to Investigate Metabolic Priming by Methionine Restriction. Methods Mol Biol 1866:61-73 (2019). Read more (PubMed: 30725408) »
  • Piggott L  et al. Acquired Resistance of ER-Positive Breast Cancer to Endocrine Treatment Confers an Adaptive Sensitivity to TRAIL through Posttranslational Downregulation of c-FLIP. Clin Cancer Res 24:2452-2463 (2018). Read more (PubMed: 29363524) »
See all 4 Publications for this product

Customer reviews and Q&As

There are currently no Customer reviews or Questions for ab59047.
Please use the links above to contact us or submit feedback about this product.

For licensing inquiries, please contact partnerships@abcam.com

Sign up